Status:

WITHDRAWN

The KetoGlioma (Ketogenic Glioma) Study

Lead Sponsor:

Tufts Medical Center

Conditions:

Glioma

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

This research is being conducted to see if patients diagnosed with high grade gliomas can adhere to the supplemented High-Fat Low-Carbohydrate (sHFLC) + KetoPhyt diet, and to see how this diet might a...

Detailed Description

This study is designed to analyze the feasibility of using the sHFLC + KetoPhyt as an anti-cancer agent against glioblastoma multiforme (GBM). While the classic ketogenic diet typically uses a 4:1 rat...

Eligibility Criteria

Inclusion

  • Patients with high-grade gliomas (World Health Organization \[WHO\] Grade III/IV) with newly diagnosed or recurrent disease
  • Ability to understand and willingness to sign an informed consent form prior to any study procedures
  • For patients treated with external beam radiation (XRT), interstitial brachytherapy or radiosurgery, an interval of \> 4 weeks must have elapsed from completion of XRT to pre-registration.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2
  • Recovered to Common Terminology Criteria for Adverse Events (CTCAE) grade 1 or less toxicity from other agents with exception of alopecia.
  • Steroid dosing stable for at least 7 days
  • Adequate organ function as defined by the following laboratory values:
  • Absolute neutrophil count (ANC) ≥ 1500/mm3
  • Platelet Count ≥ 100,000/mm3
  • Creatinine ≤ 1.5 mg/dl x upper limit of normal (ULN)
  • Creatinine Clearance ≥ 45 mL/min
  • Total Bilirubin ≤ 1.5 x ULN (except in cases of Gilbert's disease)
  • AST (aspartate aminotransferase)/ ALT (alanine transaminase) ≤ 2.5 x ULN

Exclusion

  • Concurrent investigational agents or other glioma-directed therapy (chemotherapy, radiation) while on study.
  • Pregnant or breastfeeding

Key Trial Info

Start Date :

May 18 2022

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 18 2022

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT05373381

Start Date

May 18 2022

End Date

May 18 2022

Last Update

February 2 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Tufts Medical Center

Boston, Massachusetts, United States, 02111

The KetoGlioma (Ketogenic Glioma) Study | DecenTrialz